Citations

Mayo Clinic

Clear

2372 citation(s) found for "Long, Qi".

Long-Term Cardiovascular Adverse Events in Patients with Chronic Myelogenous Leukemia Treated with Tyrosine Kinase Inhibitors
Zureigat, Hadil, Mohamed, Ahmed N, Govande, Sneha, Zabor, Emily C, Alchirazi, Muaz Alsabbagh, Dhakal, Aastha, Mushtaq, Ali, Rehman, Naveen, Foster, Parker, Elghoul, Yasmine, Berube, Bryan, Ramonfaur, Diego, Francis, Brandon, Jain, Akriti G, Molina, John C, Balderman, Sophia, Singh, Abhay, Gerds, Aaron T, Advani, Anjali S, Carraway, Hetty E, Kalaycio, Matt, Mukherjee, Sudipto, Moudgil, Rohit, Mustafa Ali, Moaath K

The Oncologist | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag459 Get It

Abstract Background patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) are at risk for cardiotoxicity. Risk estimates from clinical trials may be limited by healthier populations and short follow-up durations. Materials and Methods we evaluated the incidence of cardiovascular adverse events (CVD-AE) and echocardiographic changes as a secondary outcome in CML patients on TKIs, accounting for cardiovascular risk from prior TKI exposure. CML patients treated with TKIs at Cleveland Clinic (2007–2022) were included. TKIs analyzed were imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Data included demographics, comorbidities, treatments, and follow-up. Outcomes were overall survival and major adverse cardiovascular events (MACE): acute coronary syndrome (ACS), heart failure, stroke, peripheral arterial disease, and revascularization. Pleural effusions, pericardial effusions and pulmonary hypertension were assessed. Echocardiograms were collected at baseline. Multivariable Cox regression and generalized linear mixed models were applied. Results among 357 patients (median age 56; 57% male; 85% White), 518 CVD-AE occurred during median follow-up of 7.2 years. Compared with imatinib, nilotinib was associated with increased ACS (HR 3.5, P = 0.02), dasatinib with heart failure (HR 2.5, P = 0.04), and dasatinib, and asciminib with pleural (HRs 3.5, 5.8; P < 0.05) and pericardial effusions (HR 5.1, 21.6; P < 0.05). Dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02). MACE incidence did not differ significantly among TKIs. Among 69 patients with serial echocardiograms, ponatinib decreased left ventricular ejection fraction (β = −5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037). Conclusion Cardiovascular risks differ among TKIs, and therapy duration influences echocardiographic changes.
A translational platform for brain-computer interfaces and adaptive neuromodulation: Technical characterization, long-term validation, and implementation of the CorTec brain interchange-BCI2000 ecosystem
Lampert, Frederik , Baker, Matthew R , Engelhardt, William , Gkogkidis, C Alexis , Ayyoubi, Amir Hossein , Fazli Besheli, Behrang , Boom, Max van den , Kellar, Douglas J , Kim, Inyong , Staff, Nathan P , Schalk, Gerwin , Ince, Nuri Firat

Journal of Neural Engineering | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1088/1741-2552/aec198 | PMID 43019594 Get It

Abstract Objective: Adaptive neuromodulation systems and implantable brain-computer interfaces (BCIs) are promising therapies for neurological and psychiatric disorders. However, their broader translation into research and clinical practice remains limited by technological complexity, restricted access to implantable research platforms, and the lack of standardized, reproducible experimental workflows. We therefore aimed to develop and validate an open, general-purpose translational ecosystem that enables rapid development, evaluation, and dissemination of novel neuromodulation and implantable BCI paradigms.
Approach: The CorTec Brain Interchange (BIC) implantable neural sensing and stimulation device was integrated with the open-source BCI2000 platform to create a modular, extensible neuromodulation ecosystem. We established a standardized battery of quantitative assessments to characterize implantable neuromodulation systems to comprehensively evaluate the CorTec BIC device through benchtop characterization, long-term preclinical in vivo validation, and a human feasibility demonstration using the benchtop BIC system connected to externalized leads.
Results: Comprehensive benchtop characterization of the BIC device independently validated previously reported performance while extending its evaluation through quantification of recording noise, acquisition and stimulation latencies, and validation of impedance measurements. Long-term in vivo validation in five canines, with the longest implantation exceeding three years, demonstrated stable chronic recordings while also capturing progressive deterioration of individual channels through longitudinal changes in signal quality and impedance. The ecosystem enabled active functional decoding more than two years after implantation, closed-loop stimulation using arbitrary spectral biomarkers, capturing brain stimulation evoked potentials, detection of epilepsy-associated biomarkers and observational assessment of their response to stimulation. In addition, we translated an established one-dimensional BCI cursor-control paradigm to the BIC benchtop system, demonstrating ecosystem portability and feasibility with a human participant. Finally, we share surgical protocols, imaging and analysis pipelines, datasets, and software to facilitate reproducible neuromodulation research.
Significance: We present a versatile, open-source translational ecosystem that supports a wide range of neuromodulation and implantable BCI applications with minimal modification. By combining comprehensive hardware characterization with standardized software tools and experimental workflows, this work provides a practical reference for researchers adopting the BIC platform while establishing a broadly applicable framework for systematic characterization of implantable neuromodulation systems. The ecosystem lowers technical barriers to implantable neurotechnology research, promotes reproducibility, and provides a foundation for accelerating the development and clinical translation of next-generation adaptive neuromodulation and implantable BCI therapies for patients with neurological and psychiatric disorders.
Long-term economic benefits of early cancer detection through enhanced multimodal screening: a modeling study of whole-body MRI and liquid biopsy
Sato, Ryoko , McVeigh, Kim H, Bolan, Candice, Brar, Pamila, Sazama, Naomi, Karow, David

Journal of Comparative Effectiveness Research | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.57264/cer-2026-0099 | PMID 43012102 Get It

Aim: Cancer poses a substantial health and economic burden in the US Although early detection is associated with improved outcomes and lower treatment costs, many cancers are still diagnosed at advanced stages. Enhanced multimodal screening combining whole-body magnetic resonance imaging (WB MRI) and blood-based multicancer early detection (MCED) may shift diagnoses earlier, but its long-term economic impact remains uncertain. Materials & methods: We developed an economic model to estimate expected cancer-related costs under two scenarios: status quo with conventional screening and enhanced multimodal screening incorporating WB MRI and MCED. The analysis included common cancers with an annual incidence of ≥10,000 new cases in the US in 2025. Expected cancer management costs were estimated using incidence-based 5-year stage-specific medical costs. Productivity losses were estimated using a simplified human capital approach, applying published stage-specific work-loss durations to sex-specific annual earnings. Under the intervention arm, conservative, moderate and maximum cancer stage-shift assumptions were evaluated. These scenarios reflected increasing degrees of earlier cancer detection, with a greater proportion of cancers assumed to be diagnosed at earlier stages rather than at advanced stages. Total expected cancer-related costs per person were derived by combining direct medical costs and productivity losses, weighted by cancer risk and stage distribution. Results: Under the status quo, expected cancer-related costs were estimated at $74,431 for men and $78,818 for women. With enhanced multimodal screening under the moderate stage-shift assumption, costs, including screening and false positive workup, declined to about $66,000 and $69,500, respectively, representing approximately 12% reduction. Under the conservative stage-shift assumption, total costs were similar to those under the status quo, whereas under the maximum stage-shift assumption, cost reductions ranged from 24.0% to 24.3% for men and from 24.7% to 25.0% for women. Conclusion: Enhanced multimodal screening may reduce the economic burden of cancer by shifting diagnosis toward earlier stages, although the magnitude of benefit depends substantially on the extent to which cancers are detected at earlier stages in practice. These findings highlight the potential long-term economic value of earlier cancer detection while underscoring the need for prospective evidence on the real-world performance of WB-MRI and MCED screening strategies. Because long-term real-world data for population-level WB-MRI and MCED screening remain limited, these findings should be interpreted as estimates of potential economic impact rather than projections of a specific screening program.
Abstract 9024: Real-World Emulation of the ALONE Atrial Fibrillation Trial: Long-Term Anticoagulation Strategies After Catheter Ablation in a United States Health System
de Sousa Barzon Serra, Vinicius, Zanco, Julia, Ibrahim, Ramzi, Abdul Nabi, Hussein, Shamoun, Fadi, Ayoub, Chadi, Arsanjani, Reza, Scott, Luis R

Circulation | November 8, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.9024 Get It

Background: The ALONE-AF randomized trial demonstrated that discontinuing oral anticoagulation (OAC) at least one year after catheter ablation for atrial fibrillation (AF) in patients free of arrhythmia recurrence reduced the composite of stroke, systemic embolism, and major bleeding versus OAC continuation. Whether this benefit generalizes to a broader real-world United States population has not been established. Hypothesis: We hypothesized that among adults with a CHA 2 DS 2 -VASc score ≥1 (men) or ≥2 (women) who remained free of atrial arrhythmia recurrence for at least one year after AF catheter ablation, OAC discontinuation would be associated with a lower risk of a composite clinical outcome compared with OAC continuation. Methods: We conducted a target trial emulation using multi-site electronic health record data from a United States academic health system. Patients undergoing AF catheter ablation between October 2015 and December 2022 who met ALONE-AF eligibility criteria were assigned to OAC discontinuation (intervention) or OAC continuation (comparator) at day 91 after the index date (defined as 365 days post-ablation). The primary outcome was a composite of ischemic stroke, systemic embolism, major bleeding, and all-cause mortality, with administrative censoring at 365 days. Kaplan-Meier estimates, log-rank tests, and unadjusted and adjusted Cox proportional hazards models were performed. Four prespecified sensitivity analyses were conducted. Results: Among 4,217 eligible patients (OAC discontinuation n=3,781; OAC continuation n=436), the cumulative composite event rate at 365 days was 3.94% versus 7.11%, respectively (event-free survival 0.961 vs 0.929; log-rank p=0.0017). OAC continuation was associated with a higher hazard of the composite endpoint in unadjusted (HR 1.84, 95% CI 1.25-2.71; p=0.002) and adjusted (HR 1.72, 95% CI 1.14-2.60; p=0.009) models. Results were consistent across prespecified sensitivity analyses (HR range 1.59-1.99 across completed analyses). Conclusions: In this real-world emulation of the ALONE-AF trial, OAC discontinuation one year after AF catheter ablation in patients free of arrhythmia recurrence was associated with a lower composite risk of stroke, systemic embolism, major bleeding, and all-cause mortality compared with OAC continuation. These findings support the generalizability of the ALONE-AF results to a broader United States population.
Abstract 9614: Right Ventricular-Pulmonary Artery Coupling as a Superior Predictor of Long-Term Mortality After Percutaneous Mitral Valve Interventions: A Retrospective Single-Center Experience
Rivera, Frederick, Tsai, Chieh-Mei, Lahr, Brian, Lee, Alexander, Lara-Breitinger, Kyla, McCully, Robert B, Oh, Jae K, Alkhouli, Mohamad Adnan, Rihal, Charanjit, Guerrero, Mayra E

Circulation | November 8, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.9614 Get It

Background: TAPSE/RVSP, the ratio of tricuspid annular plane systolic excursion to right ventricular systolic pressure, is an echocardiographic surrogate of RV-pulmonary arterial (RV-PA) coupling that integrates contractile reserve with afterload. Its comparative prognostic value versus TAPSE alone has not been established in large, contemporary percutaneous mitral valve cohorts. Hypothesis: Pre-procedural RV-PA uncoupling (TAPSE/RVSP ≤0.33 mm/mmHg) independently predicts long-term all-cause mortality and outperforms TAPSE alone in patients undergoing transcatheter mitral edge-to-edge repair (mTEER) or transcatheter mitral valve replacement (TMVR). Methods: This retrospective analysis included 525 consecutive patients undergoing mTEER or TMVR at Mayo Clinic (January 2015-December 2025). Uncoupled was defined as TAPSE/RVSP ≤0.33 mm/mmHg (n=259) versus coupled >0.33 (n=266). Kaplan-Meier survival estimates were compared by likelihood ratio testing. Cox proportional hazards models with restricted cubic splines evaluated TAPSE/RVSP and TAPSE as mortality predictors, unadjusted and adjusted for age, sex, Charlson comorbidity index, LVEF, and MR severity. Discrimination was assessed by C-index and adequacy index. Interaction analyses by sex and procedure type were performed. Results: Among 525 patients, 186 deaths occurred over median follow-up 2.8 years (IQR: 0.8-5.2). Uncoupled patients had significantly worse survival at 1 year (74.7% vs. 89.2%), 3 years (56.7% vs. 72.6%), and 5 years (38.8% vs. 58.3%; p=0.002), with early and sustained curve divergence. ( Figure 1 ) Abnormal TAPSE (≤1.7 cm) also predicted worse outcomes, though with less distinct separation (p=0.021). ( Figure 2 ) In unadjusted analysis, TAPSE/RVSP outperformed TAPSE alone (C-index: 0.619 vs. 0.585; adequacy: 0.99 vs. 0.45). After multivariable adjustment, TAPSE/RVSP remained an independent predictor (HR: 1.74, 95% CI: 1.12-2.68; p=0.002), whereas TAPSE lost significance (p=0.122). Partial effects plots demonstrated a monotonic inverse association between TAPSE/RVSP and log-relative hazard in unadjusted (p<0.001) and adjusted (p=0.002) models; TAPSE splines attenuated to non-significance after adjustment. TAPSE/RVSP provided incremental prognostic value beyond TAPSE (partial χ 2 =10.0, p=0.018). ( Figure 3 ) Conclusion: Pre-procedural RV-PA uncoupling assessed by TAPSE/RVSP is a superior independent predictor of long-term mortality after percutaneous mitral valve interventions compared to TAPSE alone, with consistent effect across sex and procedure type. Routine pre-procedural reporting of TAPSE/RVSP may improve risk stratification for patients undergoing mTEER or TMVR.
Abstract 9325: GLP-1 Receptor Agonists and Long-Term Survival in a Large Real-World Cohort of Patients with Obstructive Sleep Apnea
Razaghi, Mahshad, Farina, Juan, Scalia, Isabel G, Awad, Kamal, Abdelfattah, Fatmaelzahraa E, Hafez, Abdelrahman, Ahmed, Sherif, Chollet, Laureve, Nour, Mohamed, Ayoub, Chadi, Arsanjani, Reza

Circulation | November 8, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.9325 Get It

Background: Obstructive sleep apnea (OSA) is known to be associated with significant cardiometabolic morbidity and premature mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help in reducing weight, inflammation, and cardiovascular risk, but their impact on mortality in unselected OSA populations remains unknown. Methods: This retrospective cohort study included all patients diagnosed with OSA across three Mayo Clinic sites (Arizona, Florida, and Minnesota) from January 2016 to December 2024. Use of GLP-1RA was modeled as a time-dependent covariate within multivariable Cox proportional hazards models, adjusted for age, sex, diabetes mellitus, and body mass index (BMI). To minimize baseline confounding, 1:1 propensity score matching (PSM) was conducted using a nearest-neighbor algorithm. In addition, subgroup analyses were conducted with formal interaction testing and stratified by sex, age, diabetes mellitus status, and BMI. A sensitivity analysis restricted to patients diagnosed from 2022 onward separately evaluated GLP-1RAs versus dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Hypothesis: We hypothesized that GLP-1RA use is associated with reduced all-cause mortality in patients with OSA, with greater benefit observed among dual GLP-1/GIP receptor agonist users. Results: Among 136,782 patients with OSA (mean age 59.1±16.6 years; 60.4% male), 24,205 (17.7%) received GLP-1RAs. Five-year overall survival was higher among GLP-1RA users compared with non-users (95.1% vs 89.6%; log-rank p<0.001), Figure 1. In multivariable time-varying analysis, GLP-1RA use was independently associated with lower all-cause mortality (HR 0.82, 95% CI 0.75-0.91; p<0.001). This association persisted after PSM (17,601 matched pairs; HR 0.89, 95% CI 0.80-0.99; p=0.028). The survival benefit was consistent across sex-, age-, and diabetes-defined subgroups, with no significant interactions observed, Figure 2. In a post-2022 sensitivity analysis, both GLP-1RAs (HR 0.58, 95% CI 0.50-0.67) and dual GLP-1/GIP receptor agonists (HR 0.41, 95% CI 0.29-0.57) were associated with lower mortality compared with untreated patients (both p<0.001), with a greater magnitude of benefit observed among dual agonist users. Conclusions: In this large real-world cohort of patients with OSA, GLP-1RA use was independently associated with lower all-cause mortality with consistent benefits across age, sex, and diabetes subgroups. Dual GLP-1/GIP receptor agonists were associated with a greater reduction in mortality than GLP-1RAs alone. These findings support future evaluation of GLP-1-based therapies as a potential mortality-modifying strategy in OSA.
Abstract 18275: Artificial Intelligence-ECG Age Gap Predicts Postoperative Outcomes and Long-Term Mortality Following Mitral Valve Intervention
Danesh, Sina, Schaff, Hartzell V, Kumar, Harendra, Tang, Paul C, Aslahishahri, Masoomeh, Holst, Kimberly, Greason, Kevin, Rowse, Phillip, Friedman, Paul, Eleid, Mackram F, Todd, Austin, Attia, Zachi, Lopez-Jimenez, Francisco, Dearani, Joseph A, Crestanello, Juan A, Arghami, Arman

Circulation | November 8, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.18275 Get It

Background: Artificial intelligence-enabled electrocardiography (AI-ECG) age has emerged as a digital biomarker of biologic aging. While AI-ECG age gap has been associated with mortality in various cardiovascular populations, its role in surgical risk stratification among patients with mitral valve (MV) disease remains poorly defined. Hypothesis: We sought to evaluate the association between preoperative AI-ECG age gap and both long-term mortality and postoperative outcomes among patients undergoing MV surgery. We hypothesized that increasing AI-ECG age gap would identify patients at higher risk for adverse postoperative events and long-term mortality. Methods: We identified 13640 patients who underwent MV surgery at our institution between 1993 and 2025. After excluding patients with prior cardiac surgery, age <18 years, active endocarditis, urgent/emergent procedures, and concomitant CABG, SAVR, aortic surgery, or myectomy, 6097 patients comprised the final cohort. Of these, 5435 had a valid preoperative AI-ECG age estimate from an ECG obtained within 30 days before surgery. AI-ECG age gap was defined as AI-ECG age minus chronological age. Multivariable Cox proportional hazards and restricted cubic spline analyses were performed to evaluate the association between AI-ECG age gap and all-cause mortality. Multivariable spline models were additionally used to evaluate associations with postoperative atrial fibrillation, blood transfusion, operative mortality, and hospital length of stay. Models were adjusted for chronological age, sex, body mass index, MV replacement, concomitant tricuspid valve repair, atrial fibrillation, diabetes, hypertension, and ejection fraction. Results: Among 5,435 patients (mean chronological age 61.8 years, mean AI-ECG age 62.1 years), 1,444 deaths occurred during a median follow-up of 8.5 years. Overall, 54% of patients demonstrated a positive AI-ECG age gap. Adjusted spline analyses demonstrated a graded increase in mortality risk with increasing AI-ECG age gap and each 5-year increase in AI-ECG age gap was independently associated with a 12% higher risk of long-term mortality (adjusted HR 1.12, 95% CI 1.07-1.16; P<0.001). Higher AI-ECG age gap was also associated with postoperative atrial fibrillation (adjusted OR per 5-year increase 1.08, 95% CI 1.03-1.12; P<0.001), blood transfusion (adjusted OR 1.05, 95% CI 1.01-1.10; P=0.026), longer hospital length of stay (P=0.007) and operative mortality (adjusted OR 1.48, 95% CI 1.02-2.14; P=0.040). Conclusions: Preoperative AI-ECG age gap is independently associated with long-term mortality following MV surgery and demonstrates a graded relationship with adverse postoperative outcomes. These findings support AI-ECG age gap as a marker of biologic aging and may enhance preoperative risk stratification beyond chronological age alone.
Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long‐Term Outcomes
Tam, Vincy , Schaff, Hartzell V. , Thao, Viengneesee , Houten, Holly K. Van , Frye, Robert L. , Greason, Kevin L. , AlJamal, Yazan , Spencer, Philip J. , Rowse, Phillip G. , Crestanello, Juan A.

Journal of the American Heart Association | November 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.126.053850 | PMID 42998247 Get It

ABSTRACT: Background Type 2 diabetes (T2D) is common among patients undergoing coronary artery bypass grafting (CABG), but optimal post‐CABG glucose‐lowering therapy remains uncertain. Methods We conducted a retrospective cohort study using the OptumLabs Data Warehouse of adults with T2D undergoing isolated CABG from 2012–2024. Follow‐up began 30 days after discharge. Glucose‐lowering therapy was modeled as a time‐varying exposure with patients contributing no‐observed‐therapy person‐time until the first qualifying post‐discharge fill. Pairwise comparisons used stabilized inverse probability of treatment weighting. The primary outcome was all‐cause mortality; secondary outcomes were heart failure hospitalization, stroke, and repeat coronary revascularization. Results Among 19,237 patients, 24.9% had no observed post‐discharge therapy, 42.8% received metformin, 22.9% received insulin, and 9.4% received GLP‐1RA/SGLT2i therapy. All active therapies were associated with lower mortality compared with no observed therapy, including GLP‐1RA/SGLT2i (HR 0.71, 95% CI 0.58–0.87), metformin (HR 0.60, 95% CI 0.55–0.66), and insulin (HR 0.75, 95% CI 0.67–0.84). Among active therapies, metformin was associated with lower mortality than insulin (HR, 0.61 [0.54–0.70]); GLP‐1RA/SGLT2i comparisons with metformin and insulin were less precise. Metformin was also associated with lower cumulative incidence of heart failure hospitalization than no observed therapy and insulin, and lower stroke incidence than insulin. Conclusions Observed glucose‐lowering therapy initiation after CABG was associated with lower mortality compared with no observed therapy across all active treatment groups. These findings highlight a potential care gap and suggest that proper initiation of diabetes therapy after CABG represents an important opportunity to improve long‐term outcomes following surgical revascularization.
Abstract 10921: Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes
Tam, Vincy, Schaff, Hartzell V, Thao, Viengneesee, Van Houten, Holly, frye, robert, Greason, Kevin, AlJamal, Yazan, Spencer, Philip, Rowse, Phillip

Circulation | November 6, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.10921 Get It

Background: Type 2 diabetes mellitus (DM) is common among patients undergoing coronary artery bypass grafting (CABG) and is associated with adverse long-term outcomes. Although contemporary glucose-lowering therapies confer cardiovascular benefit in broad populations, optimal post-discharge diabetes management after CABG remains uncertain. Hypothesis: Initial post-discharge DM therapy after CABG is associated with differential long-term survival and cardiovascular outcomes. Methods: Using the OptumLabs Data Warehouse, we analyzed adults with type 2 DM undergoing isolated CABG from 2012-2024. Patients were classified by initial post-discharge therapy: no treatment, metformin, insulin, or glucagon-like peptide-1 receptor agonist/sodium-glucose cotransporter-2 inhibitor (GLP-1RA/SGLT2i) therapy. Patients were censored at treatment change. Stabilized inverse probability of treatment weighting was used to balance baseline covariates. Weighted Cox models evaluated all-cause mortality, heart failure hospitalization, stroke, and repeat coronary revascularization. Results: Among 19,237 patients, 4,791 (24.9%) had no observed post-discharge diabetes therapy, 8,231 (42.8%) received metformin, 4,401 (22.9%) received insulin, and 1,814 (9.4%) received GLP-1RA/SGLT2i therapy. Compared with no treatment, all active therapies were associated with lower mortality: GLP-1RA/SGLT2i (hazard ratio [HR] 0.07, 95% CI 0.04-0.11), metformin (HR 0.21, 95% CI 0.18-0.24), and insulin (HR 0.14, 95% CI 0.11-0.17; all p<0.001). GLP-1RA/SGLT2i therapy was associated with lower mortality than metformin (HR 0.25, 95% CI 0.15-0.40; p<0.001), whereas mortality did not differ between GLP-1RA/SGLT2i and insulin or between metformin and insulin. GLP-1RA/SGLT2i and metformin were also associated with lower risks of heart failure hospitalization (HR 0.79, 95% CI 0.65-0.96; p=0.02 and HR 0.60, 95% CI 0.53-0.67; p<0.001) and stroke (HR 0.57, 95% CI 0.40-0.83; p<0.01 and HR 0.73, 95% CI 0.61-0.88; p<0.001) compared with no treatment. Repeat revascularization did not differ across groups. Conclusions: Nearly one-quarter of patients with type 2 DM had no observed post-discharge diabetes therapy after CABG. Active therapy was associated with lower mortality and selected cardiovascular outcomes, and GLP-1RA/SGLT2i therapy was associated with lower mortality compared with metformin. Initial diabetes therapy after CABG represents a modifiable opportunity for long-term secondary prevention among patients with type 2 DM.
Abstract 15067: Coronary Artery Bypass Grafting for Acute Spontaneous Coronary Artery Dissection: Procedural Success, Graft Patency, and Long-Term Outcomes
Taheri, Maryam, Khawajah Barzani, Izad, Crestanello, Juan A, Hayes, Sharonne N, Tweet, Marysia S

Circulation | November 6, 2026 | Volume: 154 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.154.suppl_1.15067 Get It

Background: Coronary artery bypass grafting (CABG) is a revascularization strategy for patients with high-risk spontaneous coronary artery dissection (SCAD), particularly those with left main or multivessel SCAD; failed percutaneous coronary intervention (PCI); or hemodynamic instability. However, contemporary data on early procedural outcomes, graft patency, and long-term clinical outcomes remain limited. Methods: We performed a retrospective analysis of Mayo Clinic SCAD Registry patients who underwent CABG for acute SCAD between 1996 and 2020. Baseline clinical presentation, angiographic characteristics, procedural details, graft characteristics, and outcomes were analyzed. Kaplan-Meier analyses were performed to assess major adverse cardiovascular events (MACE) defined as death, recurrent SCAD, myocardial infarction (MI), stroke/transient ischemic attack, or repeat revascularization. Results: This cohort included 72 patients treated with CABG for acute SCAD. Mean age was 42±9 years, and 97% were women. Upon presentation, 68% had STEMI, 31% had NSTEMI; and 26% had cardiac arrest/ventricular arrhythmia. Left main SCAD was present in 35%, and multivessel SCAD in 46%. CABG was emergent in 99% and performed after failed PCI in 40%. Mechanical circulatory support was required in 54%. A total of 142/143 grafts were successfully performed as planned. Left internal mammary artery grafts were used in 53 patients (76%), and saphenous vein grafts were used in 54 patients (76%), while radial artery and right internal mammary artery grafts were infrequent (1.4% each). On-pump CABG was performed in 74%. Mean cardiopulmonary bypass time and mean aortic cross-clamp time were 75±37 and 56±21 minutes, respectively. Thirty-day postoperative complications occurred in 40%, including bleeding requiring re-exploration, cardiogenic shock, respiratory failure, ventricular arrhythmias, and severe left ventricular dysfunction. Angiography after CABG in 21 (29%) patients showed with graft occlusion in 9/21 (42.9%) at median time of 4 years (IQR 2.4-7.3). Causes of graft failure included competitive native LAD flow after vessel healing (most frequent in 88%), thrombotic occlusion, and graft obstruction. The estimated 5-year MACE rate was 32%. Conclusions: CABG remains an important revascularization strategy for high-risk SCAD, achieving high procedural success, but also high risk of early complications. Long-term graft patency is limited, and patients have a notable risk of future MACE. These findings provide one of the largest contemporary assessments of CABG outcomes in SCAD and support the need for careful surveillance following surgical revascularization.